Organogenesis Holdings Inc (NASDAQ:ORGO) shares, rose in value, without any change to the previous day’s close as strong demand from buyers drove the stock to $2.98.
Actively observing the price movement in the last trading, the stock closed the session at $2.98. The PE ratio was 81.20 over 12-month period. Referring to stock’s 52-week performance, its high was $4.70, and the low was $1.79. On the whole, ORGO has fluctuated by 13.74% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 454.69M, with a low estimate of 100.2M and a high estimate of 101.9M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 101.05M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ORGO’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 33.69, with the price of ORGO currently trading nearly 4.80% and -1.57% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.82, while the 7-day volatility ratio is showing 4.07% which for the 30-day chart, stands at 5.94%. Furthermore, Organogenesis Holdings Inc (ORGO)’s beta value is 1.54, and its average true range (ATR) is 0.16.
A comparison of Organogenesis Holdings Inc (ORGO) with its peers suggests the former has fared considerably weaker in the market. ORGO showed an intraday change of 0.00% in last session, and over the past year, it grew by 44.66%%.
Data on historical trading for Organogenesis Holdings Inc (NASDAQ:ORGO) indicates that the trading volumes over the past 3 months, they’ve averaged 755.56K. According to company’s latest data on outstanding shares, there are 131.32 million shares outstanding.
Nearly 41.43% of Organogenesis Holdings Inc’s shares belong to company insiders and institutional investors own 44.57% of the company’s shares. The stock has fallen by -27.14% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ORGO stock heading into the next quarter.
